| Name | Title | Contact Details |
|---|
Central Brace and Limb Co. is a Indianapolis, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ConsumerMedical is a leading healthcare decision support and concierge company serving approximately 3 million individuals through some of the nation`s largest employers` health plans and private exchanges. As a Medical Ally` ConsumerMedical guides participants throughout their healthcare journey with compassionate` high-touch support and deep clinical expertise. ConsumerMedical offers a fully integrated suite of solutions including Medical Decision Support` Expert Medical Opinions` Claims Advocacy and more` helping individuals and families navigate the healthcare system while reducing unnecessary elective surgeries and driving patients to the highest quality providers. The result is better care for patients` more empowered healthcare decisions for employees and their families` and a better bottom line for business. Headquartered outside Boston in Pembroke` MA` ConsumerMedical employs over100 people.
This is the Home Page for the Website.
Capital Senior Living Corporation is one of the nation`s largest operators of residential communities for senior adults. With a goal of offering affordable housing and an enriched lifestyle to thousands of seniors, our dedicated team of professionals succeeds in providing quality care in each of our unique communities.
More than 20,000 genes make us human. Genes control critical aspects of health and disease — but what controls our genes? Foghorn® Therapeutics ($FHTX) is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order. By manipulating this system with our unique Gene Traffic Control™ platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease. With Gene Traffic Control™ Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.